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license (http://creativetau, is constrained because similar changes can be found in brains of cognitively normal individuals.
Butyrylcholinesterase (BChE), which becomes associated with these structures in AD, could elevate
the accuracy of AD diagnosis by focusing on BChE pathology in the cerebral cortex, a region of scant
BChE activity in healthy brain.
Methods: N-methylpiperidin-4-yl 4-[123I]iodobenzoate, a BChE radiotracer, was injected intrave-
nously into B6SJL-Tg(APPSwFlLon, PSEN1*M146 L*L286 V) 6799Vas/Mmjax (5XFAD) mice
and their wild-type (WT) counterparts for comparative single photon emission computed tomography
(SPECT) studies. SPECT, computed tomography (CT), and magnetic resonance imaging (MRI)
enabled comparisonofwholebrain and regional retentionof theBChE radiotracer inbothmouse strains.
Results: Retention of the BChE radiotracer was consistently higher in the 5XFAD mouse than in
WT, and differences were particularly evident in the cerebral cortex.
Discussion: Cerebral cortical BChE imaging with SPECT can distinguish 5XFAD mouse model
from the WT counterpart.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Butyrylcholinesterase; Acetylcholinesterase; Single-photon emission computed tomography;Molecular imaging; Neuroimaging; 123Iodine; Alzheimer mouse model with 5 familial mutations1. Introduction
Alzheimer’s disease (AD) is a common cause of dementia
[1]. Presently, AD diagnosis is definitively confirmed at au-
topsy by detecting cerebral pathology including b-amyloid
(Ab) plaques and tau neurofibrillary tangles (NFTs) [2]. To
improve clinical diagnosis, positron emission tomography
(PET) molecular imaging has been used to visualize Ab andthor. Tel.: (902) 473-2490; Fax: (902) 473-7133.
ltan.darvesh@dal.ca
16/j.trci.2017.01.005
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).NFT in living brain [3–9]. These agents represent a leap
forward in detecting the presence of Ab and tau pathology
[10]. However, the presence of Ab in cognitively normal indi-
viduals (10%at 50 years to 44%at 90 years) andNFTs in non-
AD tauopathies limits the predictive value of these methods
for AD diagnosis [10–16]. Although cognitively normal
individuals with PET amyloid positivity may represent
preclinical stages of AD, conversion to AD has not yet been
shown [17,18]. Therefore, the need is great for biomarkers
to enhance existing armamentarium for AD diagnosis.
Neuronal loss, particularly cholinergic, contributes to
cognitive and behavioral symptoms of AD [19–21]. Withimer’s Association. This is an open access article under the CC BY-NC-ND
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(AChE) and an increase in the levels of the related enzyme
butyrylcholinesterase (BChE), that accumulate in plaques
and tangles in the brain [22,23]. This accumulation of BChE
in plaques and tangles enables differentiation of AD from
old age [23]. The observation that there is scant BChEdetected
histochemically in thenormal cerebral cortex, but accumulates
there in association with AD pathology, suggests an opportu-
nity to detect this pathology during life by imagingBChE [24].
Pioneering work in cholinesterase imaging provided PET
probes targeting AChE [25–30] and BChE [26,31,32]. For
example, N-[11C] methylpiperidin-4-yl acetate ([11C]
MP4A) could monitor AChE activity in vivo in the AD brain
[33]. Imaging BChEmet less success using the butyrate ester
of N-[11C]methylpiperidinol, which entered the brain, but
without increased radioligand uptake in regions that typi-
cally accumulate BChE-associated AD plaques [26,31,34].
Moreover, decreased uptake in AD brain compared to
normal brain was observed, in contrast to histochemical
and isolation studies of this enzyme [23,25,35–38].
A recent autoradiographic study [39], using a cholines-
terase radioligand, phenyl 4-[123I]iodophenylcarbamate,
was able to distinguish AD amyloid plaques from those
found in the cerebral cortex of cognitively normal brains.
However, in further in vivo studies, this radiotracer did not
provide satisfactory brain retention. Prospective substrate-
type 123I SPECT radioligands containing the N-methylpiper-
idinol moiety were designed to prolong ligand-enzyme la-
tencies [39,40]. Ex vivo autoradiographic evidence was
earlier reported for N-methylpiperidin-4yl 4-[123I]
iodobenzoate, which, injected intravenously into a rat,
entered the brain and labeled areas known to exhibit BChE
activity in histochemical studies [40]. In the present study,
we extend this work by using dynamic SPECT images to
evaluate BChE engagement and compare uptake, retention,
and brain distribution of N-methylpiperidin-4-yl 4-[123I]io-
dobenzoate radiotracer in the B6SJL-Tg(APPSwFlLon,
PSEN1*M146 L*L286 V) 6799Vas/Mmjax (5XFAD)
mouse model compared to that in its wild-type (WT) coun-
terpart [41]. The 5XFAD model accumulates Ab plaques
that have BChE activity, as in human AD [42,43]. This
animal model has significant BChE pathology over an
aggressive course of amyloidosis [43]. The increased activity
of this enzyme in the brain, compared to theWT counterpart,
makes this model well suited for examining the potential of
BChE imaging agents preclinically, as a proof of principle.
Significantly, higher radiolabel retention in the 5XFAD
brain, particularly in the cerebral cortex, would hold promise
for such agents as imaging biomarkers for AD diagnosis.2. Materials and methods
Formal approval to conduct these experiments was ob-
tained from the Dalhousie University Radiation Safety Com-
mittee (overseen by the Canadian Nuclear Safety
Commission).2.1. Synthesis/biochemical materials
Na123I in 0.1 N NaOH was obtained from MDS Nordion.
Other chemicals and solvents were purchased from Sigma
Aldrich (Canada). Isoflurane gas mixtures were diluted
with oxygen. Ultraviolet (UV) analysis was on Ultrospec
2100 pro UV/Visible Spectrophotometer (Biochrom) with
Swift II software (Amersham). High-performance liquid
chromatography (HPLC) purifications were on an Agilent
1260 Infinity HPLC with ZORBAX Eclipse XDB-C18,
4.6 ! 250 mm, 5 mm column (Agilent Technologies), and
a RediFrac fraction collector (Amersham Biosciences).2.2. Enzyme specificity
To determine murine BChE specificity for N-methylpiper-
idin-4-yl 4-iodobenzoate [40], repetitive scans for change in
absorbance used mouse serum as enzyme source. Briefly, in
a quartz cuvette, to a reaction mixture of 0.1 M phosphate
buffer (2 mL, pH 7.4) containing 0.1% gelatin; 5XFAD serum
(200 mL); and either (1) 50%(aq) acetonitrile (60 mL, no inhib-
itor), (2) 1mMethopropazine (60mL, BChE inhibitor), or (3)1
mM BW 284C51 (60 mL, AChE inhibitor) in 50%(aq) acetoni-
trile, and mixed [44]. Reaction was initiated with 1 mM
N-methylpiperidin-4-yl 4-iodobenzoate in 50%(aq) acetonitrile
(30mL).TheUVabsorbance of eachmixturewas scanned from
200 to 300 nm every 30 minutes for a total of 3.5 hours.2.3. Synthesis and labeling of radiotracer
Synthesis of N-methylpiperidinol-4-yl 4-[123I]iodoben-
zoate was performed with modification of the procedure
described previously [40]. Briefly, in a plastic microtube
(250 mL), Na123I (w157 MBq) in 0.1 M NaOH(aq) (17 mL)
was diluted with 0.1 M NaOH(aq) (10 mL), then acidified
with 0.1 M HCl(aq) (32 mL), followed by addition of N-meth-
ylpiperidin-4-yl 4-(tributylstannyl)benzoate in acetonitrile
(50 mL, 4.6 mM). The reaction was initiated by adding
N-chlorosuccinimide in acetonitrile (50 mL, 3mM).After vor-
texing (7.5 minutes) the mixture at room temperature, 0.1 M
NaOH(aq)was added (13mL). Precursor andnonradioactive io-
dobenzoate established HPLC retention times. Radiolabeled
product was purified using HPLC with 80% methanol(aq) at
2 mL/minute as eluent. Fractions were collected every 30 sec-
onds for 10 minutes. Collected fractions containing pure N-
methylpiperidinol-4-yl 4-[123I]iodobenzoate were combined
and solvent evaporated at 40

C under a stream of argon. The
radiochemical yield, on average,was 83%, based onHPLC ra-
diograms and was consistent with radioscanned thin-layer
chromatography (TLC) experiments that determined radio-
chemical purity to be .98%. Radiotracer was re-dissolved
in 0.9% saline (0.4 mL) for animal administration.2.4. Animals
Mice were cared for according to guidelines set by the Ca-
nadian Council on Animal Care; research was approved by
D.R. DeBay et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 3 (2017) 166-176168Dalhousie University Committee on Laboratory Animals.
Pairs of female WT (C57BL/6J ! SJL/J F1, stock number:
100012-JAX) and male transgenic hemizygous 5XFAD mice
[B6SJL-Tg(APPSwFlLon, PSEN1*M146 L*L286 V)
6799Vas/Mmjax, stock number: 006554-JAX] were obtained
from The Jackson Laboratory (Bar Harbor, ME, USA) and
cared for as described previously [43]. Imagingwas performed
during light phase of the light–dark cycle. A total of 5 female
mice (5XFAD n 5 3, WT n 5 2) and 7 male mice (5XFAD
n 5 4, WT n 5 3) were imaged; average age was
11.16 1.1months. This agegroupwas chosen to ensure robust
deposition of pathology to increase the likelihood of detecting
differences in BChE activity between WTand 5XFAD mice.2.5. SPECT/CT imaging
Micewereweighed immediately before imaging, anesthe-
tized with 3% isoflurane in an induction chamber, restrained
in a Tailveiner Restrainer (Braintree Scientific) while under a
continuous stream of 1.5% isoflurane. Mice were secured in
prone position in a magnetic resonance (MR)-compatible an-
imal bed. N-methylpiperidin-4-yl 4-[123I]iodobenzoate
(17.65–44.77MBq in 0.9% saline (140–200 mL)) was admin-
istered through a lateral tail vein catheter line and subse-
quently flushed with saline. Mice were wrapped in a
blanket on a heated bed, maintained under continuous stream
of 1.5%–2% isoflurane and respiration rate monitored for the
duration of scan (SA Instruments Inc., Stony Brook, NY,
USA). Themouse head regionwas centered on a 14mm axial
field of view (FOV); dynamic SPECT frames (four projec-
tions per frame) were acquired in super list mode (SLM)
over three 5minutewindows followed by four 10minutewin-
dows with a SPARK (Cubresa Inc., MB, Canada) single-head
standalone benchtop SPECT scanner integrated with a Tri-
umph XO LabPET preclinical computed tomography (CT)
scanner (TriFoil Imaging, CA, USA). After initial scanner
setup and homing cycle of the SPECT gantry, frame 1
commenced 3.5 minutes after injection with subsequent
frames acquired on average at 3.5, 9.75, 16.0, 22.5, 33.75,
45.0, and 56.75 minutes. Following SPECT scanning, a CT
scanwas acquired for anatomical reference and subsequently
coregistered with anatomical magnetic resonance imaging
(MRI) acquired in a separate scan (see Section 2.6). CT im-
ageswere collected in flymodewith a 70-kVp x-ray beam en-
ergy (160 mA beam current), 512 projections, four summed
frames/projection, with 2 ! 2 binning and magnification of
2.26X, providing complete whole-brain coverage in a 56-
mm FOV. CT scan duration was 8.5 minutes.2.6. MRI
MRI scans were performed in a separate session before
SPECT/CT imaging to facilitate regional analyses of radio-
tracer retention in the brain. MRI was carried out as
described in a previous MRI protocol [45]. Images
[(142 mm)3, full brain coverage] were acquired at 3.0 Tover 61 minutes using a 3D balanced steady-state free pre-
cession, (b-SSFP) imaging sequence (T2/T1-weighting).2.7. Image processing
Dynamic SPECT images were reconstructed over each of
seven frames acquired (three 5 minute frames and four
10 minute frames) as follows: SPECT SLM data were
converted to list mode data using built-in Cubresa SPARK
preprocessing routine at 160 keVwith a 20% energy window
applied. List mode data were reconstructed using an iterative
3D maximum-likelihood expectation maximization algo-
rithm (nine iterations) using HiSPECT software (SciVis
Inc.). Resultant SPECT images yielded an effective in-
plane resolution of 0.7 mm. Dark image and quantitative cal-
ibrations were performed weekly for the duration of the
study and applied to each image acquired.
CT images were reconstructed with a 512 ! 512 ! 512
image matrix over a 56 mm FOV using built-in optimum
noise reconstruction procedures with the Triumph XO CT
acquisition software, yielding images with (102 mm)3
isotropic resolution. Fusion of SPECT and CT images was
achieved using established coordinate transformations be-
tween the two modalities, whose common coordinate frames
were applied in AMIDE imaging analysis software [46]. Im-
ages were assessed by visual inspection to ensure accurate
fusion results. MRI images underwent 3D maximum inten-
sity projection processing of four-phase cycle frequencies
and resulting reconstructed images were zero-padded (inter-
polated to higher resolution grid to increase the effective res-
olution and image quality) in ImageJ (NIH, USA).2.8. SPECT/CT/MRI coregistration and dynamic SPECT
regional analysis
Intermodality registration performedbetweenSPECT/CT/
MRI andaMR-based 3Ddigitalmouse atlas permitted parcel-
lation of the brain for regional analyses as described previ-
ously [45,47]. A six-parameter rigid body registration was
performed between mouse MR and a standard brain from
which the digital atlas was derived using Automated Image
Registration 5.3.0 [48]. Higher spatial transformations (warp-
ing)were applied to standard brain and correspondingwarped
MRatlas.MRI andwarpedMRatlas, alongwith SPECT/CT–
fused images,were imported intoAMIDE,where affine regis-
tration between modalities was carried out [46].
SPECT regions of interest (ROI) statistics were generated to
determine N-methylpiperidin-4-yl 4-[123I]iodobenzoate reten-
tion for six ROIs defined by the MR atlas: (1) whole brain, (2)
cerebral cortex, (3) hippocampal formation, (4) amygdala, (5)
thalamus, and (6) basal ganglia. Composite ROIs were derived
using fslmaths scripts using threshold and subtraction com-
mands carried out in FSL (Oxford,UK).Whole-brainROIs con-
tained all atlas brain structures excluding the cerebellum and
brainstem. “Rest-of-brain” masks were also generated for each
brain structure investigated, comprised ofwhole brain excluding
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zoate retention values in raw time activity curves are reported
as the average (mean voxel value) percent injected dose per
mLof brain tissue (%ID/mL). Retention indiceswere computed
for each ROI, expressed as relative standardized uptake values
(SUVRs) with each rest-of-brain internal reference tissue
(represented as SUVRROI 5 SUVROI/SUV(whole brain - ROI)).
This metric was used to limit any possible intersubject or
interscan variability.
2.9. BChE histochemistry
Brain tissue processing and BChE histochemistry were
carried out as described previously to generate photomicro-
graphs of BChE distributions in 5XFAD and WT mouse
brains [42].
2.10. Statistical analysis
Unpaired t-tests (single tailed, assuming unequal vari-
ances) of group means (5XFAD vs WT) were carried out
at each time-activity curve interval for both %ID/mL and
SUVRmetrics. Differences were concluded at a significance
level of 5% (P , .05, *), 1% (P , .01, **), and trends were
identified at (P , .10, y). All data are presented as group
means 6 standard error of the mean (SEM). All statistical
tests were performed in Excel (Microsoft Office, version
15.13.1).Fig. 1. 5XFAD mouse serum hydrolysis of N-methylpiperidin-4-yl
4-iodobenzoate demonstrated by repetitive UV scans at 30 minute intervals
over 3.5 hours in 0.1 M phosphate buffer (pH 7.4). (A) Without inhibitor
added (inlay shows probe chemical structure). (B) In the presence of
BChE inhibitor ethopropazine. (C) In the presence of AChE inhibitor,
BW 284C51. No effect on hydrolysis in the presence of BW 284C51. Ab-
breviations: AChE, acetylcholinesterase; BChE, butyrylcholinesterase;
5XFAD, B6SJL-Tg(APPSwFlLon, PSEN1*M146 L*L286 V) 6799Vas/
Mmjax mouse strain; UV, ultraviolet.3. Results
3.1. Synthesis of N-methylpiperidin-4-yl 4-[123I]
iodobenzoate
The radiotracer was prepared and purified using modifi-
cations to an earlier procedure [40]. Here, acetonitrile re-
placed methanol as reaction solvent to prevent ester
methanolysis. Reaction time was reduced (15 minutes to
7.5 minutes) by continuous vortexing once reactants were
combined. Better separation and purification of product by
HPLC was effected by making the reaction mixture slightly
alkaline with 0.1-M NaOH(aq) instead of NaHCO3(aq). These
modifications provided radiochemical yields .80%, radio-
chemical purity .98%, and calculated specific activity of
approximately 4500 GBq/mmol.
3.2. Cholinesterase specificity for 1-methylpiperidin-4-yl
4-iodobenzoate
The nonradioactive iodobenzoate was examined using
mouse serum containing both AChE and BChE. As indicated
in repetitive scans (Fig. 1A), the ester underwent slow hydro-
lysis at pH 7.4 over 210 minutes. When mouse serum was
first treated with BChE inhibitor, ethopropazine, under the
same conditions, no hydrolysis occurred (Fig. 1B) [44]. In
contrast, AChE inhibitor, BW 184C51, showed no effect
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teracts with BChE over AChE [44].Fig. 2. (A) Representative WT (left) and 5XFAD (right) dynamic SPECT/CT brai
indicate initial uptake and blood–brain barrier penetrance of radiotracer by 3.5minu
retention in the 5XFAD brain compared toWT. Image intensities expressed as perce
mL–32%ID/mL. (B) Corresponding whole-brain radiotracer SPECT time-activity c
greater cerebral retention is evident in 5XFAD compared to WT. *Denotes statistic
Abbreviations: CT, computed tomography; SEM, standard error of the mean; WT
6799Vas/Mmjax mouse strain; SPECT, single photon emission computed tomogr3.3. Dynamic SPECT imaging
After injection of N-methylpiperidin-4-yl 4-[123I]iodo-
benzoate, dynamic SPECT scans of mouse brain weren images in sagittal, axial, and coronal planes. SPECT activity source maps
te post-injection (PI) in bothWTand 5XFAD brains, with greater radiotracer
nt injected dose per mL (%ID/mL) are set to a common color scale of 0%ID/
urves for 5XFAD (blue) andWT (green) mice (mean6 SEM). Significantly
ally significant differences (P, .05); yIndicates a statistical trend (P, .10).
, wild-type; 5XFAD, B6SJL-Tg(APPSwFlLon, PSEN1*M146 L*L286 V)
aphy.
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frames. Dynamic SPECT frames generated 472,846 to
1,044,089 counts for 5 minute frames and 671,233 to
1,901,199 counts for 10 minute frames. These count levels
provided sufficient signal-to-noise ratio and reconstructed
image quality for assessment of brain uptake and retention
of radiotracer. SPECT, CT, and MRI image registration pro-
vided robust and reproducible affine and nonlinear registra-
tion of these modalities with corresponding MR-based
digital atlas [45]. From this, comparisons of brain retention
of radiotracer could be assessed in 5XFAD and compared to
WT mice.Fig. 3. Photomicrographs showing representative BChE histochemical
staining at midcoronal level in WT (top) and 5XFAD (bottom) brains.
Note little BChE staining in cerebral cortex of WT mice and marked eleva-
tion of BChE in cerebral cortex of 5XFAD mice. Significant accumulation
of BChE in subcortical regions is also apparent, beyond that observed in the
WT brain. Scale bar5 1 mm and 100 mm (inlay). Abbreviations: A, amyg-
dala; BChE, butyrylcholinesterase; BG, basal ganglia; CC, cerebral cortex;
H, hippocampal formation; Th, thalamus; WT, wild-type; 5XFAD, B6SJL-
Tg(APPSwFlLon, PSEN1*M146 L*L286 V) 6799Vas/Mmjax mouse
strain.3.4. Whole-brain retention of radioligand
Dynamic SPECT images (Fig. 2A) and corresponding
time-activity curves (Fig. 2B) permitted semiquantitative
comparison of radiotracer retention between 5XFAD and
WT groups over the entire whole brain imaging session. Re-
sults described represent pooled male and female data
because no sex differences were observed (separate analysis,
not shown).
Both WT and 5XFAD strains showed rapid uptake of
radiotracer into the brain (Fig. 2A and 2B), indicating it
readily crossed the blood–brain barrier. Shown in the time-
activity curves (Fig. 2B), by 3.5 minutes after ligand injec-
tion, radioactivity is clearly visible in both 5XFAD and
WT mouse brains (Fig. 2A). Time-activity curves
(Fig. 2B) indicate subsequent washout of radiotracer in
5XFAD andWT brains within 15–20minutes after injection.
In each time frame up to 60 minutes, there was greater (up to
2.3-fold) retention of label in 5XFAD brains relative to WT.
Heterogeneous distribution of radiolabel throughout the
whole brain (Fig. 2A) was evident. Distribution differences
of radiolabel in WT and 5XFAD brains could reflect areas
of high BChE-associated AD pathology. Radiotracer assess-
ment of the regional distribution demonstrated specific pat-
terns of retention that distinguish 5XFAD brains from WT
controls.3.5. Comparative histochemical- and SPECT-visualized
regional butyrylcholinesterase activity
Histological analysis represents the “gold standard” for
detection of BChE activity in brain tissue and indicates a het-
erogeneous distribution of the enzyme throughout the brain.
For example, as observed in the normal human brain, WT
mouse brain (Fig. 3, top) exhibits very little BChE histo-
chemical staining in the cerebral cortex [23,38]. However,
the cerebral cortex of 5XFAD shows marked BChE
accumulation [42,43] (Fig. 3, bottom). Because both the ce-
rebral cortex and subcortical regions, such as the hippocam-
pal formation and thalamus, develop BChE-associated AD
pathology, it may be assumed that a region such as the cere-
bral cortex, that normally has little BChE activity, may
provide the greatest contrast for detecting BChE-associated AD pathology (Fig. 3) than would subcortical re-
gions that express BChE in the absence of AD pathology.
This notion is supported by semiquantitative analyses of
SPECT radiolabel retention (Fig. 4). To compare potential
differences in radiotracer retention between 5XFAD and
WT brains, several different regional metrics were tested
to generate time-activity curves. ROIs examined included
the cerebral cortex, basal ganglia, hippocampal formation,
amygdala, and thalamus (Figs. 3 and 4).3.6. Cortical and subcortical retention comparisons
Time-activity curves for regional comparisons (Fig. 5) of
5XFAD and WT images (expressed as %ID/mL) showed
similar trends in each ROI to observe for whole-brain evalu-
ation (Fig. 2B). This was true for the cerebral cortex (Fig. 5A)
as well as some subcortical structures (Fig. 5B–5E). It is
evident that it depends on the ROI examined as to whether
significant differences in retention of radiotracer could iden-
tify AD pathology through BChE association. For example,
comparing robust retention in the cerebral cortex of
5XFAD relative to WT (Fig. 5A) with that in the amygdala
(Fig. 5E), where there is no significant difference detected
for the retention in the two strains. A summary graph of
Fig. 4. ComparisonofBChEactivity atmidcoronal level (as inFig. 3) in specificbrain regionsofWT(left) and 5XFAD(right)micedetectedwith radiotracerSPECT
analysis. (A) CTwith coregisteredMR. (B) SPECT images acquired at 4-minute post-injectionwith coregistered CT/MR andROIs.Marked retention in the 5XFAD
cerebral cortex is evident in the 5XFAD brain compared to WTwith less difference in retention evident in amygdala, hippocampus, basal ganglia, and thalamus.
Image intensities expressed as%ID/mL and set to a common scale of 0%ID/mL–40%ID/mL. Abbreviations: A, amygdala; BChE, butyrylcholinesterase; BG, basal
ganglia; CC, cerebral cortex; CT, computed tomography; H, hippocampal formation; MR, magnetic resonance; ROIs, regions of interest; SPECT, single photon
emission computed tomography; Th, thalamus; WT, wild-type; 5XFAD, B6SJL-Tg(APPSwFlLon, PSEN1*M146 L*L286 V) 6799Vas/Mmjax mouse strain.
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WT time-activity curves is presented for the cerebral cortex
and subcortical areas in Fig. 5F.All ROIs show the same trend
of greater radiotracer retention in 5XFAD brain relative to
WT save the amygdala. However, the greatest difference in
radiotracer retention over time (w3-fold) is seen for the cere-
bral cortex. Because increased BChE accumulation in cere-
bral cortex is a prominent feature of AD progression, it is
of value to assess the relative proportion of radiotracer in
the brain that can be attributed to the cortex [22,23,38].
The cortical retention index, a relative SUV
(SUVRc.cortex/(whole brain-c.cortex)) metric that expresses tracer
retention in the cortex normalized to radiotracer uptake in
the rest of the brain, serves as a means to assess cortical
retention while limiting interscan and intersubject
variability between scans. With this metric, the cortical
retention index was found to be significantly greater (18%–
31%) in 5XFAD brain than in WT controls (Fig. 6A), which
was sustained over the 60 minutes of study. This is indicated
by the ratio of label retention in 5XFAD cerebral cortex over
that of WT controls being consistently on the order of 1.2 to
1.3 over each time point examined (Fig. 6B).4. Discussion
A number of approaches have been undertaken to develop
biomarkers for definitive diagnosis ofAD, includingPETbrain
imaging of amyloid and tau. Several amyloid imaging agents
have been approved as ancillary agents to test for AD and tau
imaging agents are being developed [6–9]. However, because
amyloid plaques and tau neurofibrillary tangles can also be
found in cognitively normal individuals, development of
additional biomarker targets seems imperative to improve the
diagnosis of AD during life [10,11]. Changes in components
of the cholinergic system, such as the appearance of BChE
associated with AD pathology in the cerebral cortex, provide
an opportunity to image this pathology without registering
similar anomalies that may also be present in the brains of
many cognitively normal individuals. Thus, BChE may
represent a viable diagnostic imaging target which must be
carefully considered. In other dementias, such as dementia
with Lewy bodies and vascular dementia, there are no
reported increases in levels of BChE [49,50]. However, for
tauopathies, BChE radiotracers will need to be evaluated in
appropriate mouse models to determine their specificity.
Fig. 5. Corresponding N-methylpiperidin-4-yl 4-[123I]iodobenzoate time-activity curves for 5XFAD (blue) and WT (green) mice. Mean 6 SEM. *Denotes
statistically significant differences (P , .05), yIndicates a statistical trend (P , .10). (A) Sustained retention in the cerebral cortex over each dynamic frame
was observed in 5XFAD compared to WTup to 60 minutes. (B) A similar trend of sustained retention was observed in basal ganglia up to 60 minutes. (C) Early
retention in hippocampus was greater in the 5XFAD brain up to 30 minutes. (D) A similar trend of early retention was seen in the thalamus up to 30 minutes. (E)
No differences were observed in amygdala retention between 5XFAD andWTover the entire time course. (F) Ratio of 5XFAD toWT time-activity curvemeans
indicating the fold difference (increase) in radiotracer retention in the cerebral cortex (blue), basal ganglia (light blue), hippocampus (orange), thalamus (pink),
and amygdala (purple) relative to WT controls. Cerebral cortex retention was approximately 3.5 fold greater at 4-minute post-injection and was maintained at
approximately 2.5 fold up to 60-minute postinjection. Abbreviations: AD, Alzheimer’s disease; SEM, standard error of the mean; WT, wild-type; 5XFAD,
B6SJL-Tg(APPSwFlLon, PSEN1*M146 L*L286 V) 6799Vas/Mmjax (5XFAD).
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zoate selectively engages with BChE and undergoes slow
hydrolysis (Fig. 1). This radiotracer crosses the blood–brainbarrier, and there is greater retention in brains of the 5XFAD
mouse model than WT counterparts (Fig. 2). Dynamic
SPECT imaging analysis measuring differential retention
Fig. 6. A) N-methylpiperidin-4-yl 4-[123I]iodobenzoate retention indices for
5XFAD (blue) andWT (green) mice. Mean6 SEM. (A) Cortical retention in-
dex (SUVRc.cortex/(whole brain-c.cortex): cortical retention normalized to rest-of-
brain) was 18%–31% greater in 5XFAD brains versus WT over the
60-minute imaging window. *,**Denote statistically significant differences
(P, .05, P, .01, respectively). (B) Fractional difference in cortical retention
index between 5XFAD andWT indicating between 1.18–1.31X greater reten-
tion in the cerebral cortex of 5XFAD mice compared to WT. Abbreviations:
AD, Alzheimer’s disease; SEM, standard error of the mean; SUVR,
relative standardized uptake value; WT, wild-type; 5XFAD, B6SJL-
Tg(APPSwFlLon, PSEN1*M146 L*L286 V) 6799Vas/Mmjax mouse strain.
D.R. DeBay et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 3 (2017) 166-176174of radioactivity in the cerebral cortex and various subcortical
regions (Fig. 4) revealed known histochemical BChE activ-
ity (Fig. 3). Time-activity curves derived from dynamic
SPECT analysis consistently indicate elevated retention of
radioactivity in brains of 5XFAD mice compared to WT
counterparts (Figs. 2 and 5), that is particularly evident in
the cerebral cortex (Figs. 5 and 6).
In previous attempts, N-methylpiperidinyl acetate and pro-
prionate could image AChE in the human brain, whereas N-
methylpiperidinyl butyrate, a specific substrate for BChE,
entered the brain and accumulated in certain regions [34], but
it was unable to distinguish AD from normal brain [24,26–
28,34]. It is not clear why N-methylpiperidinyl butyrate
could not recapitulate what is known from postmortem brain
histochemistry. There are several possibilities that include
nonspecific or off-target binding of the tracer or that the radio-
active atom (11C) is located on the side of the ester molecule
that is thefirst leavinggroup during theBChE-catalyzedhydro-
lysis. This could cause the radioactive atom being rapidlydispersed away from the target. To test this possibility, a radio-
tracerwith a larger acyl groupbearing the radioactive atomwas
used. The placement of the radioactive atom (123I) on the acyl
portionof the ester ensures a longer lived enzyme-acyl interme-
diate than the earlier ligands. Altering the placement of the
radioactive atom appeared to improve the imaging outcomes
in this study. More importantly, these findings are in keeping
with earlier observations in human AD that BChE associates
with AD pathology [23,35–37]. Evidence that BChE
radiotracers can distinguish between AD pathology and that
in cognitively normal brains with pathology bodes well for
increased diagnostic performance with the development of
selective BChE targeted imaging agents for comparative
studies focused on the cerebral cortex [39].4.1. Conclusions
These preliminary findings provide in vivo evidence of
N-methylpiperidin-4-yl 4-[123I]iodobenzoate crossing the
blood–brain barrier and are suggestive of target engagement
of this radioligand with BChE-associated pathology in the
cerebral cortex of the 5XFAD brain. The present study dem-
onstrates that BChE-specific radiotracers can be developed
as AD diagnostic agents. This work opens avenues for
further investigations to determine the temporal association
of BChE accumulation in pathology using SPECT BChE ra-
diotracers in this and other preclinical models and, ulti-
mately, in human AD.Acknowledgments
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1. Systematic review: A significant amount of effort in
recent Alzheimer’s disease (AD) research has been in
the quest to identify noninvasive biomarkers (e.g.,
imaging) to assist in the early diagnosis of AD during
life. The authors have reviewed the current state of
AD neuroimaging research as well as the body of
cholinesterase imaging research that has been inves-
tigated to date. These relevant citations are provided
in this article.
2. Interpretation: We have identified a butyrylcholine-
sterase-specific radiotracer that crosses the blood–
brain barrier, recapitulates the known histochemical
distribution of butyrylcholinesterase-associated Alz-
heimer pathology and has potential to augment current
clinical and brain imaging diagnostics toward an early
and definitive diagnosis of AD.
3. Future directions: These preliminary results warrant
further study to refine our understanding of the
detailed imaging characteristics of this and similar
classes of butyrylcholinesterase radiotracers.
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